Viking Global Investors LP Exact Sciences Corp Transaction History

Viking Global Investors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $298 Million - $426 Million	-2,996,604 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$72.92 - $102.01 $59.4 Million - $83 Million	814,070 Added 37.3%	2,996,604 $306 Million
Q2 2020 Aug 07, 2020	SELL	$55.75 - $92.75 $13.7 Million - $22.7 Million	-245,036 Reduced 10.09%	2,182,534 $190 Million
Q1 2020 May 13, 2020	BUY	$37.9 - $104.44 $13.7 Million - $37.6 Million	360,323 Added 17.43%	2,427,570 $141 Million
Q4 2019 Feb 13, 2020	SELL	$77.66 - $99.74 $9.16 Million - $11.8 Million	-117,986 Reduced 5.4%	2,067,247 $191 Million
Q3 2019 Nov 13, 2019	SELL	$90.37 - $122.49 $7.18 Million - $9.73 Million	-79,441 Reduced 3.51%	2,185,233 $197 Million
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $85.1 Million - $112 Million	-950,308 Reduced 29.56%	2,264,674 $267 Million
Q1 2019 May 15, 2019	SELL	$61.98 - $96.5 $46.2 Million - $71.9 Million	-745,029 Reduced 18.81%	3,214,982 $278 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $149 Million - $220 Million	2,665,361 Added 205.88%	3,960,011 $250 Million
Q3 2018 Nov 14, 2018	BUY	$48.29 - $80.6 $62.5 Million - $104 Million	1,294,650 New	1,294,650 $102 Million

674

163M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.7B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.